Search

Displaying results 5291 - 5300 of 10000 in total
  1. Drug

    Rimazolium

    go.drugbank.com/drugs/DB13289
    Experimental

    Rimazolium is an experimental analgesic drug [A176186].

  2. Drug

    Diphenyleneiodonium

    go.drugbank.com/drugs/DB17025
    Experimental

    An NADPH oxidase 2 (NOX2) inhibitor.[A252987]

  3. Drug

    Acecainide

    go.drugbank.com/drugs/DB17602
    Experimental

    Acecainide is an investigational anti-arrhythmia drug.

  4. Drug

    AM365

    go.drugbank.com/drugs/DB06564
    Experimental

    Detiviciclovir (AM365) is an antiviral nucleoside analogue.

  5. Drug

    AKI-001

    go.drugbank.com/drugs/DB07266
    Experimental

    AKI-001 is an aurora kinase inhibitor.

  6. Drug

    SU-11652

    go.drugbank.com/drugs/DB08009
    Experimental

    SU-11652 is a tyrosine kinase inhibitor.

  7. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m<sup>2</sup>. … [L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal to refuse the approval because the data submitted did not show that it was safe under the proposed

  8. Drug

    Metralindole

    go.drugbank.com/drugs/DB09306
    Experimental

    Metralindole, also known as Inkazan, is similar in structure and pharmacology to pirlindole. It functions as a reversible inhibitor of monoamine oxidase A.

  9. Drug

    SVV-001

    go.drugbank.com/drugs/DB06129
    Investigational

    SVV-001 is a solid. … SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of human cancers with neuroendocrine features.

  10. Drug

    Human papillomavirus type 33 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10311
    ApprovedInvestigational

    Human papillomavirus type 33 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 33.